Search Videos and More
Video
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
Video
ASCO26: Jennifer Ligibel, MD, BWEL
Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.
News
Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.
Document
Treatment Guideline: First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC)
The Breast Oncology Center held meetings to discuss recommendations regarding first-line treatment for patients with metastatic triple-negative breast cancer (TNBC).
News
ADC Provides Patients with Better Results Even After Subsequent Therapy for Advanced Triple-Negative Breast Cancer
A shift in the way advanced triple-negative breast cancer is treated may be on the horizon with mounting evidence that moving sacituzumab govitecan, an antibody-drug conjugate (ADC), to the first line of treatment confers long-term benefit compared to standard therapy, including continued benefit even after subsequent therapy.
News
Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
A new study from Dana-Farber Cancer Institute shows that cases of stage IV breast cancer, a common but largely difficult to treat disease, are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published today JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly, from 9.5 cases per 100,000 women in 2010 to 11.2 cases per 100,000 women in 2021. Stage IV, or de novo metastatic breast cancer, refers to cancer has already spread to distant organs at the time initial diagnosis.
News
Dana-Farber Phase 1 Study Explores Toxicity Reduction in Combination of Trastuzumab Deruxtecan and Olaparib in Advanced HER2-Expressing Malignancies
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.
News
Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026
Select presentations by Dana-Farber faculty include a promising clinical trial chemotherapy and RAS inhibitor combination for pancreatic patients, new research on mapping the tumor microbiome using the presence of microorganisms and encouraging results from a clinical trial for older patients with multiple myeloma precursor conditions.
News
Immune Activity Shift a Key Early Step in Breast Cancer Formation
Dana-Farber Cancer Institute research provides the first appreciation of the role of special immunosuppressive regulatory T cells in paving a path for precancerous ductal carcinoma in situ (DCIS) to turn into breast cancer.
Document
Treatment Guideline: Vaginal Estrogen in Patients with History of Breast Cancer
The Breast Oncology Center held meetings to discuss recommendations regarding the use of vaginal estrogen in patients with a history of breast cancer.
News
Dana-Farber Research Uncovers Approach to Activating the Immune System Against Metastatic Breast Cancer
Cancer spreads, or metastasizes, when tumor cells shed from a primary solid tumor, for example in the breast, and embed in other organs, such as the lung, liver, and brain, and begin to grow.
News
Addition of CDK 4/6 inhibitor benefits patients with HR+, HER2+ metastatic breast cancer, new study shows
The addition of a CDK 4/6 inhibitor to standard therapy in patients with “double-positive” metastatic breast cancer significantly extended the time the disease did not progress according to data published today in the New England Journal of Medicine.